Psychometric validation of the BDI-II among HIV-positive CHARTER study participants.
Title | Psychometric validation of the BDI-II among HIV-positive CHARTER study participants. |
Publication Type | Journal Article |
Year of Publication | 2015 |
Authors | Hobkirk, AL, Starosta, AJ, De Leo, JA, Marra, CM, Heaton, RK, Earleywine, M |
Corporate Authors | CHARTER Group |
Journal | Psychol Assess |
Volume | 27 |
Issue | 2 |
Pagination | 457-66 |
Date Published | 2015 Jun |
ISSN | 1939-134X |
Keywords | Adult, Anti-HIV Agents, CHARTER, Cross-Sectional Studies, Depressive Disorder, Depressive Disorder, Major, Female, HIV Long-Term Survivors, HIV Seropositivity, Humans, Internal, Male, Middle Aged, Personality Inventory, Psychometrics, Reproducibility of Results |
Abstract | Rates of depression are high among individuals living with HIV. Accurate assessment of depressive symptoms among this population is important for ensuring proper diagnosis and treatment. The Beck Depression Inventory-II (BDI-II) is a widely used measure for assessing depression, however its psychometric properties have not yet been investigated for use with HIV-positive populations in the United States. The current study was the first to assess the psychometric properties of the BDI-II among a large cohort of HIV-positive participants sampled at multiple sites across the United States as part of the CNS HIV Antiretroviral Therapy Effects Research (CHARTER) study. The BDI-II test scores showed good internal consistency (α = .93) and adequate test-retest reliability (internal consistency coefficient = 0.83) over a 6-mo period. Using a "gold standard" of major depressive disorder determined by the Composite International Diagnostic Interview, sensitivity and specificity were maximized at a total cut-off score of 17 and a receiver operating characteristic analysis confirmed that the BDI-II is an adequate diagnostic measure for the sample (area under the curve = 0.83). The sensitivity and specificity of each score are provided graphically. Confirmatory factor analyses confirmed the best fit for a three-factor model over one-factor and two-factor models and models with a higher-order factor included. The results suggest that the BDI-II is an adequate measure for assessing depressive symptoms among U.S. HIV-positive patients. Cut-off scores should be adjusted to enhance sensitivity or specificity as needed and the measure can be differentiated into cognitive, affective, and somatic depressive symptoms. |
DOI | 10.1037/pas0000040 |
Alternate Journal | Psychol Assess |
PubMed ID | 25419643 |
PubMed Central ID | PMC4442079 |
Grant List | HHSN271201000036C / MH / NIMH NIH HHS / United States F32 DA038519 / DA / NIDA NIH HHS / United States HHS-N-270-2010-00030C / / PHS HHS / United States P30 MH062512 / MH / NIMH NIH HHS / United States HHS-N-271-2010-00036C / / PHS HHS / United States |